

# openheart Obstructive sleep apnoea and atrial fibrillation: are we on time?!

Francesco Maria Angelo Brasca ,<sup>1</sup> Elisa Perger<sup>2,3</sup>

**To cite:** Brasca FMA, Perger E. Obstructive sleep apnoea and atrial fibrillation: are we on time?!. *Open Heart* 2024;**11**:e002859. doi:10.1136/openhrt-2024-002859

Accepted 15 September 2024

Editorial on 'Cardiac remodelling in patients with AF and OSA' by T-E Hunt and coauthors

The study by Hunt and coauthors focuses attention on possible positive cardiac remodelling following continuous positive airway pressure (CPAP) treatment. They analyse patients with paroxysmal atrial fibrillation (AF), mainly treated with pulmonary vein isolation (PVI), randomised to CPAP treatment or standard care, finding no significant differences in left ventricular (LV) ejection fraction, LV global longitudinal strain, left atrial volume index, left atrial reservoir strain and right atrium area.

These results seem to raise a doubt on the efficacy of CPAP treatment for obstructive sleep apnoea (OSA). This point needs to be clarified.

CPAP is the first-line treatment for OSA. Benefits on sleep disorders are well demonstrated, reducing the count of apnoea and hypopnoea per hour of sleep and the hypoxic and the hypercapnic burden. Nevertheless, despite encouraging results in observational studies, CPAP treatment has proven a neutral effect on secondary cardiovascular prevention in randomised controlled trials (RCTs).<sup>1-3</sup>

OSA has been involved in cardiovascular diseases with many pathophysiological mechanisms and, in particular, it acts both as a trigger and as a negative factor for structural modification in the setting of cardiac arrhythmias.

Specifically, recurring apnoea-hypopnoea episodes, cortical arousals from sleep, and sleep fragmentation result in sympathetic overactivity and increased serum catecholamine levels, stimulating both heart rate and blood pressure. Additionally, 1) intermittent hypoxia promotes local and systemic inflammation, 2) oxidative stress and endothelial dysfunction induce atherosclerosis and 3) intrathoracic pressure fluctuation induces mechanical damage in vascular and cardiac structure and 4) negative intrathoracic pressure impairs LV filling and reduce stroke volume by means of increased venous return.<sup>4</sup>

All these conditions contribute to structural cardiac remodelling, including LV hypertrophy and left atrial enlargement and, over time, can lead to diastolic heart failure.<sup>5</sup>

Moreover, a final pathway leading to AF could be found in the modification of electrical properties of the atria. Acute atrial stretch shortens the effective refractory period and slows the conduction velocity across the pulmonary vein-left atrium (LA) junction.<sup>6</sup> Similarly, strongly negative intrathoracic pressure activates intrathoracic baroreceptors, inducing autonomic reflex responses, which reduce the refractory period.<sup>6</sup>

In this contest, the study by Hunt has two specific strength points: the use of implantable loop recorders to assess AF episodes and burden, and the good compliance of patients to CPAP treatment.

The findings of the study are in contrast with several non-RCTs and observational studies showing a favourable relationship between reduction in sleep-disordered breathing and avoiding AF recurrence. Of note, a positive effect of CPAP has been also described in reversing atrial remodelling evaluated by increased atrial voltage, improved conduction velocity and reduction of complex ECGs at 6 months.<sup>7</sup>

In our opinion, the study by Hunt stimulates our thinking about some questions.

► Are we treating the right patients?

OSA severity can be assessed by means of different measures, nevertheless the count of apnoea-hypopnoea index (AHI) remains the official one. This study enrolled patients with with an AHI $\geq$ 15/h, while atrial reverse remodelling has been shown in patients with a more severe disease (AHI $\geq$ 45/h).<sup>7</sup> The AHI does not consider the hypoxic and hypercapnic burden related to increased cardiovascular events. An interesting research goal into the sleep medicine field could be to establish if OSA detrimental effects are more serious in specific cardiovascular risk profiles, OSA is particularly detrimental.<sup>8</sup>



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Department of Electrophysiology and Clinical Arrhythmology, Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Italy

<sup>2</sup>Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Lombardia, Italy

<sup>3</sup>Department of Medicine, University of Milan-Bicocca, Milano, Italy

#### Correspondence to

Dr Francesco Maria Angelo Brasca; fmasbrasca@gmail.com

- Few months of CPAP treatment might not be enough to reverse the negative cardiac remodelling of AF, moreover if this positive remodelling would occur in patients that show poor improvement in AF burden and blood pressure. Are we treating our patient with the correct CPAP parameters?

CPAP treatment might be tricky even when an adequate adherence to CPAP treatment is achieved, as in the study of Hunt and co. differently from other recent RCT, CPAP treatment might be tricky. Indeed, CPAP has emodynamic effects per se and might impact cardiac output in a deleterious way in some subject.<sup>9</sup> Moreover, despite reducing nocturnal hypoxia burden and sleep fragmentation, CPAP, in particular greater CPAP pressure levels, may perpetuate rather than ameliorate inflammatory processes in OSA.<sup>10</sup>

Have we waited long enough?

The deterioration in cardiac structure and electrophysiology that leads to AF takes years to develop. Few months of CPAP treatment might not be enough to reverse the negative cardiac remodelling of AF, especially if this positive remodelling would occur in patients with small variation in AF burden, episodes and blood pressure. However, we might expect that CPAP, reducing recurrent nocturnal cardiovascular stress, will be able to impact on further arrhythmias. In a study with longer follow up (48 months), OSA treatment after PVI was associated to lower blood pressure, LV mass, LA size and to paroxysmal rather than persistent AF compared with untreated OSA patients.<sup>11</sup>

Overall, it seems that the time needed to analyse AF recurrence is much shorter than that for cardiac remodelling. From this perspective, patient selection could be the most important limitation. Indeed, it is well known that benefits could be poor, both, in healthy patients without left atrial enlargement or LV impairment and in patients with more severe conditions, whose negative remodelling is too advanced for recovery.

All these speculations suggest the need for more dedicated understanding of comorbid AF in patients with OSA and patients with OSA in AF. Moreover, the recent evolution in OSA therapy also opens the field for a personalised treatment approach.<sup>12</sup>

**Contributors** Both authors contributed equally to the paper. FB is the guarantor for the paper.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Commissioned; internally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Francesco Maria Angelo Brasca <http://orcid.org/0000-0002-9998-0808>

#### REFERENCES

- 1 McEvoy RD, Antic NA, Heeley E, *et al*. SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med* 2016;375:919–31.
- 2 Peker Y, Glantz H, Eulenburg C, *et al*. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016;194:613–20.
- 3 Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, *et al*. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Respir Med* 2020;8:359–67.
- 4 Mehra R, Chung MK, Olshansky B, *et al*. American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; and Stroke Council. Sleep-Disordered Breathing and Cardiac Arrhythmias in Adults: Mechanistic Insights and Clinical Implications: a Scientific Statement From the American Heart Association. *Circulation* 2022;PMCID:e119–36.
- 5 Iwasaki YK. Mechanism and management of atrial fibrillation in the patients with obstructive sleep apnea. *J Arrhythm* 2022;38:974–80.
- 6 Calkins H, el-Atassi R, Kalbfleisch S, *et al*. Effects of an acute increase in atrial pressure on atrial refractoriness in humans. *Pacing Clin Electrophysiol* 1992;15:1674–80.
- 7 Nalliah CJ, Wong GR, Lee G, *et al*. Impact of CPAP on the Atrial Fibrillation Substrate in Obstructive Sleep Apnea: the SLEEP-AF Study. *JACC Clin Electrophysiol* 2022;8:869–77.
- 8 Mazzotti DR, Keenan BT, Lim DC, *et al*. Symptom Subtypes of Obstructive Sleep Apnea Predict Incidence of Cardiovascular Outcomes. *Am J Respir Crit Care Med* 2019;200:493–506.
- 9 Yoshida M, Dajani HR, Ando S-I, *et al*. Analysis of the effect of CPAP on hemodynamics using clinical data and a theoretical model: CPAP therapy decreases cardiac output mechanically but increases it via afterload reduction. *Sleep Med* 2024;113:25–33.
- 10 Peker Y, Celik Y, Behboudi A, *et al*. CPAP may promote an endothelial inflammatory milieu in sleep apnoea after coronary revascularization. *EBioMedicine* 2024;101:105015.
- 11 Neilan TG, Farhad H, Dodson JA, *et al*. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. *J Am Heart Assoc* 2013;2:e000421.
- 12 Perger E, Bertoli S, Lombardi C. Pharmacotherapy for obstructive sleep apnea: targeting specific pathophysiological traits. *Expert Rev Respir Med* 2023;17:663–73.